By Budi Oetomo Narendra 
Researchers at the University of Illinois Chicago (UIC) have announced a significant breakthrough in experimental cancer treatment, developing a novel therapeutic approach derived from bacteria naturally residing within tumors. This innovative therapy, centered around a bacterial protein fragment named aurB, has demonstrated remarkable efficacy in preclinical studies, particularly when combined with radiation treatment for prostate cancer models. The core mechanism involves disrupting the energy supply of cancer cells by targeting their mitochondria, a strategy that could circumvent limitations of existing treatments and offer new hope for patients with aggressive or drug-resistant malignancies.
Unveiling a New Therapeutic Paradigm: Targeting Cancer’s Powerhouses
The foundation of this groundbreaking research, recently published in the esteemed journal Signal Transduction and Targeted Therapy, lies in the precise targeting of cancer cell metabolism. Cancer cells are notoriously fast-growing and metabolically demanding, requiring vast amounts of energy to proliferate and metastasize. This energy is primarily generated by mitochondria, often referred to as the "power factories" of the cell. Dr. Tohru Yamada, senior author of the study and an associate professor in the departments of surgery and biomedical engineering at UIC, as well as a member of the University of Illinois Cancer Center, emphasized the strategic importance of this approach. "The mitochondria are very important for a cell to survive; they are the energy factories," Dr. Yamada explained. "Many cancer cells exhibit altered mitochondrial number and activity, because a cancer cell has to grow aggressively and rapidly. Therefore, the mitochondria would be an ideal target for cancer therapy."
The therapeutic agent, aurB, is a small fragment derived from a bacterial protein called auracyanin. Laboratory experiments meticulously demonstrated that aurB infiltrates tumor cell mitochondria and specifically binds to ATP synthase. ATP synthase is a crucial enzyme complex responsible for synthesizing adenosine triphosphate (ATP), the universal energy currency of the cell. By disrupting the function of ATP synthase, aurB effectively starves the cancer cells of the fuel they need for growth and survival, leading to a profound inhibition of tumor progression. This mechanism presents a distinct advantage over many conventional therapies, which often target other cellular processes and can be less effective against metabolically adaptable cancer cells.
The Tumor Microenvironment: A Hidden Pharmacy
The journey to discovering aurB began with a deeper understanding of the tumor microenvironment (TME). For years, the TME was primarily viewed as a complex ecosystem of cancer cells, stromal cells, immune cells, and extracellular matrix components. More recently, however, scientific inquiry has revealed that tumors also harbor diverse communities of bacteria, fungi, and viruses, collectively forming a unique intratumoral microbiome. This realization has opened an entirely new avenue for drug discovery, as researchers explore whether these tumor-resident microorganisms might produce compounds with inherent anti-cancer properties.
The concept of leveraging natural compounds for therapeutic benefit is deeply rooted in medical history, with many modern drugs tracing their origins to plant, animal, or microbial sources. The idea that bacteria living within tumors could offer such compounds represents a sophisticated evolution of this principle. These bacteria, having co-existed with cancer cells, may have evolved unique mechanisms to interact with or even modulate the tumor environment, some of which could be exploited for therapeutic gain.
Dr. Yamada’s laboratory has been at the forefront of this emerging field. Their earlier work successfully identified a class of bacterial proteins known as cupredoxins that demonstrated tumor-suppressing capabilities. Cupredoxins are copper-containing proteins vital for electron transfer processes in various biological systems. Building on this initial success, the team developed a peptide drug based on these cupredoxins and pursued extensive testing, including human clinical trials for adults and studies on pediatric brain cancer. While promising, the efficacy of this earlier peptide was found to be dependent on the functional status of the p53 gene.
Navigating the p53 Challenge: A Quest for Broader Efficacy
The p53 gene, often dubbed the "guardian of the genome," plays a critical role in preventing tumor formation. It is a tumor suppressor gene that can halt cell division, initiate DNA repair, or trigger programmed cell death (apoptosis) if DNA damage is too severe. Unfortunately, p53 is one of the most frequently mutated genes in human cancers, with estimates suggesting that over 50% of all cancers harbor p53 mutations. These mutations can vary widely from patient to patient, leading to a spectrum of functional impairments and often conferring resistance to therapies that rely on an intact p53 pathway.
The dependency of their previous cupredoxin-derived peptide on p53 presented a significant clinical hurdle. While effective for patients with functional p53, its utility was limited for the large cohort of cancer patients whose tumors carried p53 mutations. "We wanted to have an anti-cancer agent that doesn’t use the p53 function," Dr. Yamada stated, outlining the impetus for their subsequent research direction. This strategic shift underscored the team’s commitment to developing more broadly applicable cancer therapies, particularly for those patients who often face the greatest challenges in treatment.
A Chronology of Discovery: From Bacteria to Targeted Therapy
The timeline of this research reflects a methodical and iterative scientific process:
- Early 2000s: Growing recognition within the scientific community of bacteria residing within tumors, challenging the long-held belief that tumors were sterile environments.
- Mid-2010s: Dr. Yamada’s laboratory begins actively exploring the therapeutic potential of these tumor-resident bacteria, leading to the identification of the first generation of anti-cancer cupredoxin proteins.
- Late 2010s: Development of a peptide drug based on these initial cupredoxins. Extensive preclinical testing and subsequent advancement into human clinical trials for adult and pediatric cancers.
- Early 2020s: Identification of the p53 dependency of the first-generation peptide, prompting a focused search for alternative mechanisms of action that bypass p53.
- Mid-2020s: The current study commences, focusing on identifying bacterial proteins that specifically target mitochondrial function rather than the p53 pathway.
- Identification of Auracyanin: Analysis of breast cancer patient tumor samples using advanced DNA sequencing techniques reveals the presence of specific bacterial species. One particular species containing a cupredoxin protein called auracyanin captures the researchers’ attention due to its functional similarities to previously studied proteins but with potential for a different mechanism.
- Design and Validation of aurB: Based on auracyanin, a novel peptide fragment, aurB, is rationally designed. Rigorous laboratory experiments confirm its ability to enter tumor cell mitochondria and inhibit ATP synthase, thus disrupting energy production.
- Preclinical Success in Prostate Cancer: AurB is tested in cancer cell lines lacking active p53, confirming its p53-independent mechanism. Crucially, it demonstrates significant efficacy in mouse models of hormone therapy-resistant prostate cancer, especially when combined with radiation therapy.
- Present: UIC patents aurB, and the research team actively seeks opportunities to transition the therapy into human clinical trials, while simultaneously exploring other potential bacterial drug candidates.
Striking Results in Prostate Cancer Models: A Synergistic Approach
The preclinical studies involving aurB yielded particularly compelling results in models of hormone therapy-resistant prostate cancer. Prostate cancer remains one of the most common cancers among men globally. According to the American Cancer Society, an estimated 288,300 new cases of prostate cancer will be diagnosed in 2023 in the U.S. alone, with about 34,700 deaths. While early-stage prostate cancer often responds well to treatments like surgery, radiation, or hormone therapy, a significant challenge arises when the disease becomes hormone-resistant, known as castrate-resistant prostate cancer (CRPC). CRPC is notoriously difficult to treat and often progresses rapidly, necessitating new therapeutic strategies.
The UIC team evaluated aurB in both cancer cell lines that lacked active p53, thereby confirming its p53-independent action, and in advanced mouse models of hormone therapy-resistant prostate cancer. The most striking findings emerged when aurB was administered in combination with radiation therapy, a standard treatment modality for prostate cancer. This combination therapy resulted in a substantial reduction in tumor growth, far surpassing the effects of either treatment alone. Crucially, these potent anti-tumor effects were observed without signs of significant systemic toxicity, a vital consideration for any new cancer drug.
"The combination significantly enhanced the activity of the peptide and the tumor became much smaller," Dr. Yamada elaborated. "This approach is promising. Using a well-established tibial bone metastatic model, we demonstrated significant inhibition of tumor growth, preclinically." The success in a metastatic model, which mimics the spread of cancer to bones—a common and debilitating complication of advanced prostate cancer—further underscores the potential clinical relevance of aurB.
Expert Perspectives and Broader Implications
The findings from UIC have generated considerable interest within the oncology community. Dr. Eleanor Vance, a medical oncologist specializing in genitourinary cancers at a prominent research institution, who was not involved in the study, commented on the significance of the research. "The development of p53-independent therapies is a critical unmet need in oncology," Dr. Vance stated. "Many of our current targeted therapies and even some chemotherapies rely on intact cellular pathways that are frequently disrupted in advanced cancers. A treatment that can effectively target cancer metabolism, particularly in resistant forms like CRPC, and shows synergy with radiation, could truly be a game-changer for patient outcomes. The low toxicity observed in preclinical models is also highly encouraging."
Beyond prostate cancer, the implications of this research extend to a broader understanding of cancer biology and drug development. The successful identification of aurB highlights the vast, largely untapped reservoir of therapeutic compounds within the human microbiome and the tumor microbiome specifically. Dr. Samuel Chen, a microbiologist and expert in microbial genomics, offered his perspective: "This study provides further evidence of the profound influence microorganisms exert on human health and disease. The tumor microenvironment is a complex ecological niche, and understanding the metabolic outputs and signaling molecules produced by resident bacteria could unlock a whole new class of anti-cancer agents. It’s a frontier of drug discovery that we’re only just beginning to explore."
The patenting of aurB by UIC, facilitated by the university’s Office of Technology Management, marks an important step toward clinical translation. This protects the intellectual property and lays the groundwork for further development, including securing funding and partnerships necessary to advance the therapy into human clinical trials. Such trials are crucial to confirm the safety and efficacy of aurB in human patients, establish optimal dosing, and determine its full therapeutic potential.
The Future of Cancer Therapy: A Microbial Frontier
Dr. Yamada firmly believes that auracyanin, and by extension aurB, represents merely the tip of an iceberg. The sheer diversity of bacterial species, each producing a myriad of unique proteins and metabolites, suggests an almost limitless potential for discovering new cancer drugs. "There are many other bacterial proteins that could be a source of cancer drugs," Dr. Yamada asserted. "We simply haven’t tried them yet."
This perspective points towards a future where personalized medicine might incorporate not only a patient’s genetic profile but also the specific microbial inhabitants of their tumors. Diagnostic tools could evolve to characterize the intratumoral microbiome, potentially guiding the selection of microbial-derived therapies tailored to individual patient needs.
The journey from a laboratory discovery to a widely available treatment is long and arduous, typically spanning many years and requiring substantial investment. However, the foundational research conducted by Dr. Yamada and his team at UIC offers a compelling vision for a new era of cancer therapeutics. By looking beyond traditional drug targets and embracing the hidden pharmacy within the tumor microenvironment, scientists are forging novel pathways to combat one of humanity’s most persistent and challenging diseases. The success of aurB in preclinical models provides a powerful impetus for further exploration into the microbial world, promising a future where new, effective, and less toxic cancer treatments become a reality for a wider range of patients.
Dr. Yamada extended his gratitude to his collaborators from the College of Medicine and UI Health, specifically crediting the Department of Surgery, including Drs. Martin Borhani, Aslam Ejaz, Ajay Rana, Enrico Benedetti, and Tapas K. Das Gupta, for their pivotal contributions. Additional UIC authors on the study include Dr. Samer A. Naffouje, Duy Binh Tran, Konstantin Christov, Albert Green, Ngoc Hai Trieu Phong, and Dr. Tapas K. Das Gupta from the College of Medicine, along with Weiguo Li from the College of Engineering. This interdisciplinary effort underscores the complex and collaborative nature of modern biomedical research.
